Page 1

Consolidated Investment Analysis For GlaxoSmithKline Company Description GlaxoSmithKline plc (GSK) is a global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its pharmaceutical products include medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology and emesis. It has operations in some 114 countries and products sold in over 150 countries. The Company operates in two segments: Pharmaceuticals (prescription pharmaceuticals and vaccines) and Consumer Healthcare. In July 2009, it acquired BMS' branded generics business, which comprises a portfolio of 13 branded pharmaceuticals. In July 2009, it acquired Stiefel Laboratories, Inc. In February 2010, the Company formed a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Share Statistics

Symbol GSK Current Price 38.14 52wk Range 32.15- 42.10 Avg Vol (3m) 2,575,610

EPS 1.03 Market Cap 97.08B 52wk Change 0.05% P/E (ttm) 36.96

Financial Summary (in GBX)

On July 21, 2010, Glaxosmithkline Plc reported semi annual 2010 earnings of 59.29 per share. This result was in line with the consensus of the 2 analysts following the company and exceeded last year's results for the same period by 4.20%. The next earnings announcement is expected on February 03, 2011. Glaxosmithkline Plc reported annual 2009 earnings of 120.30 per share on February 04, 2010. GSK.L reported semi annual 2010 revenues of 14.38bn. This missed the 14.52bn consensus estimate of the 2 analysts following the company. This was 6.41% above the prior year's period results. GSK.L had revenues for the full year 2009 of 28.37bn. This was 16.49% above the prior year's results.


Analyst Consensus Buy

Outperform

Hold

Underperform

Sell

No Opinion

This is the consensus forecast amongst 40 polled investment analysts. Against the GlaxoSmithKline company. Analyst Detail

Buy

Outperform

Hold

Underperform

Sell

No Opinion

Yesterday

11

7

16

5

1

0

4 weeks ago

11

7

16

5

1

0

2 months ago

10

6

16

5

1

0

3 months ago

11

6

17

3

1

0

Last year

11

2

16

6

1

0

The 33 analysts offering 12 month price targets for GlaxoSmithKline PLC (GSK:LSE) have a median target of 1,350, with a high estimate of 1,725 and a low estimate of 1,100. The median estimate represents a 14.36% increase from the last price of 1,181. Technical Analysis Chart


Report Disclaimer DISCLAIMER DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing. This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future email regarding a specific company will be the result of an advertising and promotional campaign for which Seo Freisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly


encouraged to not use this newsletter as the basis for any investment decision. Seo Freisin and its affiliates currently hold no shares in the profiled company.

Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).


We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http:// www.finra.org

GSK  

Symbol 
 GSK
 
 
 
 EPS
 
 1.03 Current Price
38.14

 
 
 Market Cap
 97.08B 52wk Range&...

Read more
Read more
Similar to
Popular now
Just for you